Clinical trials: Genital Neoplasm, Female
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07811271
- Testing
- BG-C9074, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- BeOne Medicines
Cervical Cancer, Precancerous Condition
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
RATIONALE: Studying Pap smears in the laboratory from women with atypical glandular cells of unspecified significance may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898144
- Testing
- Papanicolaou test, laboratory biomarker analysis
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Uterine Cervical Cancer
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis cervical cancer, to evaluate the efficacy and toxic reaction.
- Trial name
- CSAPPPCC (NCT01667211)
- Testing
- albumin-bound paclitaxel plus nedaplatin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
IVF Treatment, Human Epididymal Secretory Protein E4
Serum Biomarker HE4 During IVF Treatment
Human epididymal secretory protein 4 (HE4) is a new biomarker for ovarian cancer. The effect of IVF stimulation will be evaluated in order to see whether severe hormonal changes in the gonadotrophin and steroid status affect the…
- Trial name
- FHE4 (NCT01576744)
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Turku University Hospital
Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT01494012
- Testing
- stereotactic body radiation therapy, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Uterine Cervical Neoplasm, Dietary Modification
Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients
In Mexico, cervical cancer (CC) ranks second in incidence and mortality among women. The National Institute of Cancer in Mexico (lNCan) receives annually about 500 patients with CC, 80% of which are diagnosed with locally…
- Conditions
- Uterine Cervical Neoplasm, Dietary Modification, Radiation Toxicity, Gastrointestinal Complication
- Trial name
- NCT03100409
- Testing
- Dietary modification
- Where
- Mexico
- Volunteers
- 137 people
- Sponsor
- National Institute of Cancerología
Endometrial Cancer
Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre Archive
Approximately one fourth of cases of endometrial cancer (EC) are diagnosed in premenopausal women, of whom approximately 40% wish to preserve their fertility.
- Trial name
- NCT04290299
- Testing
- Data collection
- Where
- 19 sites in United States, Australia and 14 more
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute, Naples
Prostate Cancer, Urinary Incontinence
The Effects of Pilates in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence
The purpose of this study is to compare the efficacy between a Pilates exercise program and a Pelvic Floor Muscle Training (PFMT) protocol combined with anal electrical stimulation (AES) in muscular pressure strength of the…
- Trial name
- NCT02645136
- Testing
- Pilates, PFMT and AES, Control
- Volunteers
- 115 people
- Sponsor
- Universidade Estadual de Londrina
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Depression, Anxiety
Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety
The current study intends to establish a prediction method and evaluation system for polycystic ovary syndrome (PCOS) complicated with affective disorder, such as depression and anxiety, through the epidemiological investigation.
- Trial name
- PCOS (NCT04984070)
- Testing
- Oral Contraceptives, Combined, Metformin Pill, lifestyle intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
Endometrial Cancer
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
This randomized, controlled study evaluates the efficacy of weigh loss interventions in endometrial cancer survivors, using novel technology-based weight loss platforms.
- Trial name
- NCT02466061
- Testing
- Telemedicine Weight Management plus Wi-Fi Scale (Arm A), Text for Diet (Text4Diet) Group (Arm B), Enhanced Usual Care Group (Arm C)
- Where
- 3 sites in United States
- Volunteers
- 207 people
- Sponsor
- Fred Hutchinson Cancer Center
Ovary Cancer
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs.
- Trial name
- NCT07667751
- Testing
- Sunitinib、Olaparib、Tolilizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Bai-Rong Xia
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Ovarian Cancer
Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm
Ovarian cancer is relatively rare but fatal with an annual incidence rate of 11.8 per 100 000 and a high mortality-to-incidence ratio of >0.6.
- Trial name
- NCT04214782
- Testing
- Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
- Volunteers
- 10,000 people
- Sponsor
- Tongji Hospital
Advanced Solid Tumor, Ovarian Cancer
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Trial name
- NCT05103683
- Testing
- TORL-1-23
- Where
- 14 sites in United States, South Korea
- Volunteers
- 90 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovary Cancer
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
This study looks to enroll subjects with ovarian cancer who will be having standard of care surgery to remove ovarian cancer tumors.
- Trial name
- NCT03011320
- Testing
- EC1456, 99mTc-Etarfolatide
- Where
- 2 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Endocyte
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Education, Cervical Dysplasia
Evaluating Materials to Educate Patients About Cervical Dysplasia
Primary Objective: To pilot test high and low literacy patient education materials for colposcopy clinic patients, assessing impact on patient knowledge and patient feedback about the materials.
- Trial name
- NCT00454766
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer, Metastatic Cervical Cancer
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with…
- Trial name
- NCT04943627
- Testing
- Balstilimab (BAL), Topotecan, Vinorelbine
- Where
- 3 sites in United States, Armenia
- Sponsor
- Agenus Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.